 Shares of TransCode Therapeutics Inc NASDAQ: RNAZ climbed by 65 on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. CEO Michael Dudleys remarks The preclinical study confirmed that intravenous injection of TTX-MC138 accumulates it in metastatic lesions, thereby ... The post Heres why TransCode Therapeutics stock is up about 65 on Thursday appeared first on Invezz. 